Introduction
============

Bone is dynamically molded, shaped, and repaired throughout life via coordination between bone-forming osteoblasts and bone-resorping osteoclasts ([@B2]; [@B47]). Thus, imbalances in bone remodeling can result in various osteopathic diseases, especially osteoporosis which is caused by excess osteoclast activity and includes rheumatoid arthritis, periodontal disease, multiple myelomas, and metastatic cancers, as well as osteoporosis ([@B2]; [@B43]). This disease is a common, chronic metabolic condition associated with decreased bone mass and microarchitectural deterioration; these changes lead to increased bone fragility that predisposes affected individuals to an increased risk of fractures, particularly postmenopausal women ([@B50]; [@B1]; [@B6]; [@B29]).

Postmenopausal osteoporosis (PMOP) is the most common primary form of this disease; morbidity as a result of this condition has been increasing rapidly because of changing demographics and increasing life expectancies ([@B49]; [@B3]). Numerous studies have demonstrated that estrogen deficiency is closely associated with PMOP pathogenesis ([@B49]; [@B3]; [@B28]); this is an important observation because a deficiency in this hormone is common in women after menopause ([@B28]), and it is well-established that estrogen plays a vital role in maintaining bone homeostasis and regulating remodeling ([@B3]; [@B38]). It is also clear that estrogen has a number of osteoprotective effects; on the one hand, this hormone inhibits receptor activator expression of the nuclear factor-κB ligand (RANKL), a cytokine essential for osteoclast bone resorption, and therefore suppresses the differentiation and activation of these cells. Estrogen also directly stimulates osteoblasts to secrete osteoprotegerin, a cytokine antagonist for RANKL that blocks osteoclastogenesis and bone resorption ([@B2]; [@B21]; [@B3]; [@B38]). Enhanced osteoclastogenesis contributes to the development of PMOP; thus, inhibiting the differentiation and activation of osteoclasts is a critical management strategy for this disease.

A number of therapeutic agents are currently used to treat postmenopausal women at risk of developing osteoporosis, including hormone replacement therapy ([@B6]). Although anti-osteoporotic drugs can be used to elevate bone mineral density (BMD) and reduce the risk of fractures, recent evidence suggests that their long-term use may have adverse effects on human health ([@B6]). It is therefore urgent to develop alternative agents with less side effects for the prevention and treatment of osteoporosis.

It is encouraging that natural products from medicinal plants have been shown to be valuable sources for the development of novel drugs against a range of diseases ([@B34]; [@B35]). One example is the orchid *Dendrobium officinale* ([@B51]), a traditional Chinese high-value medicinal herb that is widely used across Asia ([@B51]; [@B39]). This plant contains polysaccharides, stillnoids, alkaloids, amino acids, and trace elements and is known to exert a number of positive effects on human health ([@B26]; [@B24]), including anti-tumor, anti-oxidative, anti-chronic inflammation, anti-obesity, anti-hypertensive, hypoglycemic, neuron protection, and immune system modulation activities ([@B46]; [@B51]; [@B39]; [@B20]; [@B45]). Because of these known positive effects on human health, we hypothesize that *D. officinale* extract (DOE) will also exhibit anti-osteoporotic properties. The aim of this study is to systematically investigate whether, or not, DOE exerts anti-osteoporotic effects on *in vivo* ovariectomy-induced osteoporosis. We also evaluate the effects of this extract on *in vitro* RANKL-induced osteoclast differentiation.

Materials and Methods {#s1}
=====================

Plant Materials and Water Extract Preparation
---------------------------------------------

The stems of *D. officinale* were collected in Yunnan Province in 2011 and identified by Frof. Kaicong Fu of Peru's National Institute of Tradition Medicine. A voucher specimen (2011-DPE-1) was deposited in the Key Laboratory of Pu-erh Tea Science of Yunnan Agricultural University. The stems of *D. officinale* (134.8 g) were extracted three times with 1000 ml of water each time (30 min) under refluxed. The extract was decanted, filtered, and vacuum-dried to obtain the crude water extract 17.25 g.

Total Polysaccharides Determination
-----------------------------------

Total polysaccharides were quantified by the phenol--sulfuric acid colorimetric methods ([@B8]), using [D]{.smallcaps}-glucose as the standard. Briefly, 1.0 ml of the properly diluted sample was mixed with 1.0 ml deionized water in 10.0 ml test tube with stopper. Then, 1.0 ml phenol (5%, w/v) was added, followed by the addition of 5.0 ml H~2~SO~4~. The solution was mixed and heated in a boiling water bath for 20 min, removed, cooled 5 min in an ice bath, and the absorbance was measured at 488 nm. A standard solution of [D]{.smallcaps}-glucose was used to prepare a calibration curve. The results were expressed as milligram [D]{.smallcaps}-glucose per gram of dry extract.

Total Phenolics Determination
-----------------------------

The total phenolic content was determined according to the Folin--Ciocalteau method ([@B37]; [@B10]), using gallic acid as the standard. One milliliter of the properly diluted sample was mixed with 0.3 ml Folin--Ciocalteau reagent in a 10.0 ml volumetric flask. Then, 1.5 ml Na~2~CO~3~ (7%, w/v) was added and incubated at room temperature for 20 min, and the absorbance was measured at 760 nm. The results were calculated and expressed as milligram of gallic acid per gram of dry extract.

Total Flavonoids Determination
------------------------------

The total flavonoid content was determined by a colorimetric assay according to previous described ([@B36]). One milliliter of the properly diluted sample was mixed with 4.0 ml of EtOH (50%, v/v) in a 10.0 ml volumetric flask, then, 0.3 ml of NaNO~2~ (5%, w/v) was added. Six minutes later, 0.3 ml of Al(NO~3~)~3~ (10%, w/v) was added. After incubation for 6 min, 4.0 ml of NaOH (1.0 M) was added to the mixture, followed by the addition of 0.4 ml of EtOH (50%, v/v). The mixture solution was mixed and incubated 15 min, and the absorbance at 510 nm was measured against a blank. A standard solution of rutin was used to prepare a calibration curve. The results were expressed as milligram of rutin per gram of dry extract.

High Performance Liquid Chromatography (HPLC) Analysis
------------------------------------------------------

The crude water extract of *D. officinale* (80.0 mg) was dissolved with hot water (20 ml), then, added absolute ethyl alcohol (50 ml) and subsided in 4°C freezer overnight. The precipitate was filtrated, and the filtrate was concentrated. The residue (22.8 mg) was mixed with 1.0 ml CH~3~OH in a 2.0 ml volumetric flask, then, 1.0 ml of CH~3~OH was added. All sample solutions were filtered through a 0.45-μm MFS membrane before injection into the HPLC system. Analytical HPLC was performed on an Agilent 1260 liquid chromatograph equipped with a ZORBAX SB-C18 (4.6 × 250 mm, 5 μm) column. The optical mobile phase for the analysis was gradient elution system consisting of solvent A (water, 0.1% acetic acid) and solvent B (methyl alcohol). The gradient program was as following: 0--5 min, 25% solvent B; 5--10 min, 25--30% solvent B; 10--25 min, 30--40% solvent B; 25--45 min, 40--55% solvent B; 45--60 min, 55--70% solvent B. The detection wavelength was 280 nm. The injection volume was 10 μl. The flow rate was 1.0 ml/min, the column temperature was set 30°C.

Animals
-------

Twelve-week-old female Wistar rats (Cat. No. SCXK-(Ji)2008-0005) were obtained from the Laboratory Animal Center of Jilin University (Jilin, China). These rats were given access to normal rodent chow and water *ad libitum* and kept under a 12 h dark, 12 h light cycle for 1 week to allow them to adapt to their housing environment prior to the experiment. All animals were maintained in a room equipped with an air-filter system, while their cages and water were sterilized and replaced once daily. This study was carried out in accordance with the recommendations of the Institutional Animal Care and Use Committee of Yunnan Agricultural University (Yunnan, China). The protocol was approved by the Animal Experiments Ethics Committee of Yunnan Agricultural University.

Groups and Treatments
---------------------

Subsequent to acclimatization for 2 week, rats were either sham operated (sham group, *n* = 10) or bilaterally ovariectomized (OVX subgroup, *n* = 50) as previously described ([@B28]). Thus, following a 2-week recovery period, OVX rats were randomly subdivided into 5 groups of 10, then were given distilled water (OVX group), a Xian-Ling-Gu-Bao (XLGB) capsule (240 mg/kg body weight/day; Guizhou Tongjitang Pharmaceutical, Guizhou, China) (positive XLGB group) ([@B7]; [@B9]; [@B28]), 150 mg/kg body weight/day DOE (low treatment group), 300 mg/kg body weight/day DOE (medium treatment group), or 600 mg/kg body weight/day DOE (high treatment group) by oral gavage. XLGB capsules are common anti-osteoporosis drugs in China and have been used in clinic ([@B7]; [@B9]). The dosage of XLGB capsules in this study was determined and calculated according to prior studies ([@B28]). Animals in each group were administered their respective treatments for 13 weeks, and individual body weights were recorded weekly. Blood samples for serum and plasma isolation were collected after the last treatment administration from the abdominal artery of rats that had fasted overnight and then been anesthetized. Fresh femora from both sides as well as the uterus of each animal were then dissected and weighed. All samples were maintained in 10% neutral formaldehyde for subsequent histological analysis.

Serum Biochemical Parameter Analysis
------------------------------------

Blood samples were allowed to clot at room temperature before being centrifuged at 3,000 × *g* for 5 min at 4°C. Serum was then collected and stored at -80°C prior to analysis. The serum concentrations of total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), glucose, and alkaline phosphatase (ALP) were all measured using relevant assay kits (Shenzhen Mindray Bio-Medical Electronics, Shenzhen, China). The calcium and phosphorus levels were also measured (Zhongsheng Beikong Bio-Technology and Science, Beijing, China). The serum estradiol (E2) and bone Gla protein (BGP) levels were, respectively, determined using radioimmunoassay kits from Shenzhen Lalwen Bioengineering Technology (Shenzhen, China) and Beijing North Institute of Biological Technology (Beijing, China). The acid phosphatase (ACP) level was analyzed with kit from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). All kit procedures were followed by the manufacturer's instructions.

Determination of Organ Coefficients, Femoral Diameter, and Length
-----------------------------------------------------------------

Femur and uterus organ coefficients were calculated as followed: organ coefficient of the femur = weight of the femur/body weight; organ coefficient of the uterus = wet weight of the uterus/body weight ([@B28]), while femoral diameter and length were measured directly.

BMD and Biomechanical Assays
----------------------------

The BMD and biomechanical properties (i.e., maximum deflection and maximum load) of the left femur were measured as described previously ([@B28]), enabling calculation of femoral BMD, maximum deflection, and maximum load parameters. Briefly, BMD was automatically measured using dual-energy X-ray absorptiometry (DEXA) and biomechanical properties were evaluated by the three-point bending flexural test method ([@B9]).

Histological Analysis
---------------------

Histological analyses were performed on the uterus and right femur, again as previously described ([@B28]). Briefly, the fresh tissues of rat right femur were instantly collected, fixed in 10% neutral formaldehyde for 72 h, and removed and dehydrated. And fixed tissue samples were embedded in paraffin, cut into 4 μm sections using a slicer (Leica, Germany), and then stained with hematoxylin and eosin (H&E) and observed under a CKX41 microscope (Olympus, Tokyo, Japan). Images of cortical and trabecular bone were obtained by a BI-2000 Medical Image Analysis System (Chengdu Technology and Market Co., Ltd., Chengdu, China) and endometrial height, cortical bone thickness, and trabecular bone area were measured by a professional software.

Cell Cultures
-------------

RAW264.7 murine macrophages were purchased from the American Type Culture Collection (Manassas, VA, United States) and were maintained in DMEM high glucose medium (Thermo Fisher Scientific, Pittsburgh, PA, United States) supplemented with 10% fetal bovine serum (HyClone, San Francisco, CA, United States), and 1% penicillin/streptomycin (Solarbio, Beijing, China) at 37°C in a humidified atmosphere containing 95% air and 5% CO~2~.

Cell Viability Assay
--------------------

RAW264.7 cells (3 × 10^4^ cells/well) were then cultured with, and without, DOE (between 5 and 160 μg/ml) for either 24 or 48 h in 96-well plates. Cell viability was then determined following drug treatment using the standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma--Aldrich, St. Louis, MO, United States) method as described previously ([@B28]). Absorbance at 492 nm was measured using a microplate reader (Thermo Fisher Scientific, Pittsburgh, PA, United States), and proliferation was normalized against control cells.

*In Vitro* Osteoclastogenesis Assay
-----------------------------------

RAW264.7 cells (2 × 10^3^ cells/well) were then cultured with, and without, RANKL (50 ng/ml; R&D Systems, Minneapolis, MN, United States) in the presence of XLGB (10 μg/ml) or DOE (either 40 or 80 μg/ml) in 96-well plates. Following incubation for 5 days, a Tartrate-Resistant Acid Phosphatase (TRAP) Staining Kit (Sigma--Aldrich, St. Louis, MO, United States) was used to identify osteoclasts, following the manufacturer's instructions. Images were acquired using a digital camera attached to the microscope and the number of mature osteoclasts containing more than three nuclei was calculated, again as described previously ([@B15]; [@B43]).

Quantitative Real-Time PCR (qRT-PCR) Analysis
---------------------------------------------

RAW264.7 cells (1.2 × 10^5^ cells/well) were cultured with, and without, RANKL (50 ng/ml) in the presence of either XLGB (10 μg/ml) or DOE (40, 80 μg/ml) in 96-well plates for 48 h. Total RNA was then extracted from cultured cells using the TransZol Up Reagent (TransGen Biotech, Beijing, China), and gene expression was detected via quantitative real-time PCR (qRT-PCR) analysis which was performed using SYBR Premix Ex TaqTM II (Tli RNaseH Plus, TaKaRa Bio), as previously described ([@B28]). The primers sequences (Generay Biotech, Shanghai, China) are shown in the **Table [1](#T1){ref-type="table"}**.

###### 

The qRT-PCR primers used in this study.

  Genes           Forward (5′--3′)       Reverse (5′--3′)
  --------------- ---------------------- ----------------------
  *GADPH*         AACTTTGGCATTGTGGAAGG   ACACATTGGGGGTAGGAACA
  *TRAP*          GCTGGAAACCATGATCACCT   GAGTTGCCACACAGCATCAC
  *c-Fos*         CAAGCGGAGACAGATCAAC    TTCCTTCTCTTTCAGCAGAT
                  TTG                    TGG
  *c-Src*         CCAGGCTGAGGAGTGGTACT   CAGCTTGCGGATCTTGTAGT
  *β3-Integrin*   TGACATCGAGCAGGTGAAAG   GAGTAGCAAGGCCAATGAGC
  *Cathepsin K*   CTTCCAATACGTGCAGCAGA   TCTTCAGGGCTTTCTCGTTC
  *NFATc1*        TGGAGAAGCAGAGCACAGAC   GCGGAAAGGTGGTATCTCAA

Western Blot Analysis
---------------------

The use of western blot analysis has been described previously ([@B28]). In this study, RAW264.7 cells (4 × 10^5^ cells/well) were cultured with, and without, RANKL (50 ng/ml) in the presence of XLGB (10 μg/ml) or DOE (40, 80 μg/ml) in 60 mm plates for 48 h. Protein extracts were then prepared using the RIPA buffer (Solarbio, Beijing, China), separated using SDS--PAGE gels, transferred to PVDF membranes (Millipore, Darmstadt, Germany), and subject to immunoblotting using primary antibodies against NFATc1 (7A6), c-Src (17AT28), cathepsin K (E-7), and c-Fos (C-10) (Santa Cruz, CA, United States), as well as an antibody against β-tubulin (CST, Framingham, MA, United States).

Statistical Analysis
--------------------

All values reported here are presented as means ± the standard error of the mean (SEM) from three or more independent replicates. Data were analyzed using the one-way ANOVA and Tukey's test for independent groups; *P* \< 0.05 was considered statistically significant and representative images presented.

Results
=======

Contents of Total Polysaccharides, Total Phenolics, Total Flavonoids, and Chemical Composition Analysis
-------------------------------------------------------------------------------------------------------

Polysaccharides are reported as the major active constituents of *Dendrobium* species, and have attracted more attention with multiple pharmacological activities, such as anti-oxidant, anti-aging, anti-tumor, anti-mutagenic, and immunoregulation effects ([@B14]; [@B42]; [@B5]; [@B11]; [@B16]). The total polysaccharides contents in the water extract of *D. officinale* were determined in this work, and the values of total polysaccharides were expressed in terms of milligrams of [D]{.smallcaps}-glucose per gram dry extract. The result showed that total polysaccharides values: 5.5 ± 0.1 mg [D]{.smallcaps}-glucose/g dry extract, the reference ([@B23]) also showed a similar result. Phenolics have attracted considerable attention because of their various biological activities, including anti-oxidant, anti-tumor, anti-atherogenic, and cardioprotective effects ([@B40]). The total phenolics contents in the water extract were determined in this research, and were expressed in terms of milligrams of gallic acid per gram of dry extract. The result showed that total phenolics values: 11.4 ± 1.2 mg gallic acid/g dry extract. Flavonoids are also known to be contributors to the anti-oxidant, anti-tumor, and anti-atherogenic capacities ([@B41]). The total flavonoids content of the water extract of *D. officinale* were determined and expressed in terms of milligram of rutin per gram dry extract by comparison with standard rutin treated in the same conditions. The result showed that total flavonoids values: 17.1 ± 1.6 mg rutin/g dry extract. Compared with the previous studies ([@B14]; [@B42]; [@B5]; [@B27]; [@B11]; [@B16]; [@B48]), polysaccharide and bibenzyl are reported as the major constituents of *D. officinale*. The major chemical composition of the water extract was analyzed by HPLC system in this study. The reference characteristic of compounds (Vicenin 2, Narigenin, Daucosterol, and β-Sitosterol) was taken as control and the results are presented in **Figure [1](#F1){ref-type="fig"}**. Among the chromatographic peaks, most of them have been identified.

![HPLC chromatogram of reference characteristic of compounds: Vicenin 2 (1); Narigenin (2); Daucosterol (3); and β-Sitosterol (4).](fphar-08-00966-g001){#F1}

DOE Effects on OVX-Induced Weight Gain in Rats
----------------------------------------------

We used a model of OVX-induced osteoporosis in rats in order to investigate the effects of DOE on PMOP *in vivo*. Body weight in each group was gradually increased over the course of this experiment (**Table [2](#T2){ref-type="table"}**); thus, the rats in the OVX group weighed significantly more than their sham-operated counterparts after 6 weeks (*P* \< 0.05, *P* \< 0.01, and *P* \< 0.001). Compared with the OVX group, results show that OVX-induced body weight gains were not affected by either XLGB or DOE treatments.

###### 

Effects of DOE on body weight (g) in OVX rats.^\#^

  Time (week)   Sham           OVX               XLGB              Low-dose          Medium-dose        High-dose
  ------------- -------------- ----------------- ----------------- ----------------- ------------------ -----------------
  0             267.3 ± 19.6   266.9 ± 33.3^A^   268.9 ± 38.2^a^   266.3 ± 54.9^a^   267.4 ± 41.0^a^    266.8 ± 38.4^a^
  1             267.1 ± 19.2   282.1 ± 37.7^A^   278.2 ± 42.1^a^   285.2 ± 52.4^a^   282.1 ± 43.2^a^    271.2 ± 35.7^a^
  2             272.5 ± 21.1   283.3 ± 36.4^A^   284.8 ± 34.9^a^   296.6 ± 52.5^a^   293.4 ± 37.9^a^    283.6 ± 37.2^a^
  3             277.1 ± 20.6   289.2 ± 34.1^A^   290.0 ± 34.1^a^   306.9 ± 55.4^a^   298.3 ± 40.8^a^    295.1 ± 40.1^a^
  4             282.7 ± 21.8   301.4 ± 32.5^A^   303.3 ± 38.2^a^   320.3 ± 57.9^a^   310.21 ± 43.8^a^   304.5 ± 45.3^a^
  5             289.1 ± 21.8   311.5 ± 32.5^A^   315.3 ± 41.4^a^   329.4 ± 61.2^a^   325.7 ± 43.6^a^    314.9 ± 53.6^a^
  6             290.5 ± 21.7   321.5 ± 30.8^C^   325.0 ± 44.2^a^   339.3 ± 67.7^a^   336.8 ± 46.9^a^    324.6 ± 59.6^a^
  7             305.2 ± 27.6   331.4 ± 30.5^B^   334.1 ± 48.0^a^   346.1 ± 68.0^a^   347.7 ± 47.6^a^    332.7 ± 60.3^a^
  8             289.5 ± 24.8   336.7 ± 25.2^D^   336.7 ± 48.8^a^   347.9 ± 72.4^a^   351.9 ± 47.6^a^    337.7 ± 58.7^a^
  9             299.1 ± 30.3   345.3 ± 26.5^D^   343.3 ± 52.1^a^   358.3 ± 73.4^a^   362.3 ± 50.9^a^    345.8 ± 59.4^a^
  10            295.7 ± 31.8   353.3 ± 28.0^D^   340.0 ± 558^a^    361.7 ± 80.2^a^   368.0 ± 52.7^a^    350.9 ± 62.1^a^
  11            296.4 ± 29.6   354.4 ± 29.1^D^   345.0 ± 57.4^a^   366.0 ± 83.6^a^   372.5 ± 53.7^a^    352.4 ± 62.2^a^
  12            301.8 ± 27.3   357.2 ± 32.4^D^   350.9 ± 58.6^a^   372.8 ± 86.6^a^   374.5 ± 57.0^a^    335.1 ± 67.4^a^
  13            303.3 ± 27.4   360.9 ± 32.5^D^   353.1 ± 60.0^a^   377.2 ± 90.0^a^   377.7 ± 59.7^a^    363.5 ± 68.0^a^

\#

Data are presented as means ± SEM (

n

= 10).

A

P

\> 0.05,

B

P

\< 0.05,

C

P

\< 0.01, and

D

P

\< 0.001, OVX group compared with Sham at the same time;

a

P

\> 0.05, XLGB and DOE group compared with OVX group at the same time.

DOE Treatment Ameliorates Serum Biochemical Parameters in OVX Rats
------------------------------------------------------------------

Although treatment with DOE did not mitigate body weight gain in OVX rats, we nevertheless determined whether, or not, this extract could enhance serum biochemical parameters. Results show no significant differences in serum TC concentration in each group (**Figure [2A](#F2){ref-type="fig"}**). The TG level in the OVX group was significantly increased in comparison with the sham group (*P* \< 0.05; **Figure [2B](#F2){ref-type="fig"}**). Interestingly, treatment with both XLGB and DOE decreased the TG level in OVX rats compared with the OVX group, while a high-dose DOE treatment was most significant (*P* \< 0.05). As no significant differences were found in HDL-C, LDL-C, and glucose concentrations in each group (**Figures [2C](#F2){ref-type="fig"}--[E](#F2){ref-type="fig"}**) these results suggest that DOE treatment improved the lipid and glucose metabolisms in OVX rats to a certain degree.

![DOE treatment ameliorates serum biochemical parameters in OVX rats: **(A)** TC; **(B)** TG; **(C)** HDL-C; **(D)** LDL-C; **(E)** Glucose; **(F)** E2; **(G)** Calcium; **(H)** Phosphorus; **(I)** ALP; **(J)** BGP; and **(K)** ACP concentrations. All data are presented as means ± SEM (*n* = 10). ^∆^*P* \< 0.05, ^∆∆^*P* \< 0.01, and ^∆∆∆^*P* \< 0.001 versus the sham group, and ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, and ^∗∗∗^*P* \< 0.001 versus the OVX group.](fphar-08-00966-g002){#F2}

We then detected serum biomarkers, including E~2~, calcium, phosphorus, ALP, BGP, and ACP to further explore the effects of DOE on bone metabolism in OVX rats (**Figures [2F--K](#F2){ref-type="fig"}**). The results of these comparisons show that the E~2~ level in the OVX group decreased significantly compared with the sham group (*P* \< 0.01; **Figure [2F](#F2){ref-type="fig"}**). Thus, as expected, XLGB treatment significantly increased the E~2~ level compared with the OVX group (*P* \< 0.01). Similarly, the extent of deficiency in this compound was alleviated by treatment with DOE in medium- and high-doses exerting significant effects (*P* \< 0.05 or *P* \< 0.01).

Results show that both the calcium and phosphorus levels in the OVX group were decreased compared with the sham group, with a significant difference observed in the level of the former (*P* \< 0.01; **Figures [2G,H](#F2){ref-type="fig"}**). OVX rats treated with XLGB also experienced a significant increase in calcium and phosphorus levels compared to the OVX group, while DOE treatment significantly increased the serum levels of both these elements (*P* \< 0.05, *P* \< 0.01, or *P* \< 0.001). This result indicates that DOE can effectively maintain the homeostasis of these two elements in OVX rats.

Results also show that bone formation biomarkers, including ALP and BGP, significantly increased in the OVX group compared to the sham group (*P* \< 0.01 or *P* \< 0.001; **Figures [2I,J](#F2){ref-type="fig"}**). Interestingly, DOE treatment at medium- and high-doses significantly decreased the ALP level compared with the OVX group (*P* \< 0.05 or *P* \< 0.01), while both XLGB and DOE treatments significantly decreased the BGP level in OVX rats (*P* \< 0.05 or *P* \< 0.01). Concentration of the bone resorption biomarker ACP was significantly increased in the OVX group compared to the sham group (*P* \< 0.001; **Figure [2K](#F2){ref-type="fig"}**), while the level of this marker significantly decreased following treatments with XLGB and DOE (*P* \< 0.05 or *P* \< 0.001). These results collectively demonstrated that DOE treatment effectively ameliorates serum biochemical parameters in OVX rats.

DOE Treatment Improves Uterine and Femoral Physical Parameters in OVX Rats
--------------------------------------------------------------------------

Uterine and femoral physical parameters in OVX rats were measured to further examine whether DOE treatment protects against the damage induced by ovariectomy (**Figure [3](#F3){ref-type="fig"}**). Results show that uterine weight, the organ coefficient of the uterus, and endometrial height in the OVX group all significantly decreased compared with the sham group (*P* \< 0.001; **Figures [3A--C](#F3){ref-type="fig"}**); notably, treatment with DOE significantly enhanced these parameters compared with the OVX group (*P* \< 0.05, *P* \< 0.01, or *P* \< 0.001). The wet and dry weight of femora was almost indistinguishable between all the groups (**Figures [3D--F](#F3){ref-type="fig"}**). Compared with the sham group, organ coefficients of wet and dry femora in the OVX group significantly decreased (*P* \< 0.001; **Figures [3E--G](#F3){ref-type="fig"}**), while XLGB and DOE treatments appeared to increase these organ indices compared with the OVX group even though significant differences were not observed. Results show no significant differences in femoral diameter and length between groups, although XLGB and DOE treatments appeared to enhance these variables compared with the OVX group. These data collectively indicate that DOE treatment improves uterine and femoral physical parameters in OVX rats.

![DOE treatment improves uterine and femoral physical parameters in OVX rats: **(A)** uterine weight; **(B)** organ coefficient; **(C)** endometrial height; **(D)** femoral wet weight; **(E)** organ coefficient; **(F)** femoral dry weight; **(G)** organ coefficients; **(H)** femoral diameter; and **(I)** femoral length. All data are presented as means ± SEM (*n* = 10). ^∆∆∆^*P* \< 0.001 versus the sham group, and ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, and ^∗∗∗^*P* \< 0.001 versus the OVX group.](fphar-08-00966-g003){#F3}

DOE Treatment Improves Bone Quality in OVX Rats
-----------------------------------------------

Measures of BMD, biomechanical properties, and microarchitecture have all been widely applied to evaluate bone quality in osteoporosis models ([@B19]; [@B28]). Thus, to further investigate whether DOE treatment improved bone quality in OVX rats, we calculated the evaluation indexes outlined above (**Figure [4](#F4){ref-type="fig"}**). Comparisons with the sham group show that femoral BMD in the OVX group decreased significantly (*P* \< 0.001; **Figure [4A](#F4){ref-type="fig"}**), while compared with the OVX group, OVX-induced femoral BMD decrease was significantly reversed by XLGB and DOE treatments (*P* \< 0.05 or *P* \< 0.01). Femoral biomechanical properties, including maximum deflection and load, were also significantly decreased in the OVX group compared to the sham group (*P* \< 0.05 or *P* \< 0.01; **Figures [4B,C](#F4){ref-type="fig"}**). OVX rats treated with XLGB exhibited a marked increase in femoral maximum deflection and load compared with the OVX group (*P* \< 0.05), while DOE treatment enhanced these parameters compared to the OVX group, albeit not significantly.

![DOE treatment improves bone quality in OVX rats: **(A)** femoral BMD; **(B)** maximum deflection; **(C)** maximum load; **(D)** cortical bone tissue stained with H&E; **(E)** calculated cortical bone thickness; **(F)** trabecular bone tissue stained with H&E; and **(G)** calculated trabecular bone area. Representative images were acquired using a medical image analysis system at an original magnification of ×400. All data are presented as means ± SEM (*n* = 10). ^∆^*P* \< 0.05, ^∆∆^*P* \< 0.01, and ^∆∆∆^*P* \< 0.001 versus the sham group, and ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, and ^∗∗∗^*P* \< 0.001 versus the OVX group.](fphar-08-00966-g004){#F4}

We then directly examined and quantified femoral cortical and trabecular bone microarchitecture using H&E staining to further confirm the effects of DOE on OVX-induced osteoporosis (**Figures [4D](#F4){ref-type="fig"}--[G](#F4){ref-type="fig"}**). As expected, ovariectomies caused significant reductions in both cortical bone thickness (*P* \< 0.001; **Figures [4D,E](#F4){ref-type="fig"}**) and trabecular bone area (*P* \< 0.001; **Figures [4F,G](#F4){ref-type="fig"}**) in the OVX group compared to the sham group, while OVX rats treated with XLGB and DOE experienced a dramatic increase in cortical bone thickness (*P* \< 0.05, *P* \< 0.01, or *P* \< 0.001) as well as a striking increase in trabecular bone area (*P* \< 0.001) compared with OVX rats treated with the distilled water. Collectively, these results clearly demonstrate that DOE treatment effectively prevents *in vivo* OVX-induced osteoporosis.

DOE Treatment Inhibits RANKL-Induced Osteoclastogenesis
-------------------------------------------------------

It is well-known that excess osteoclast differentiation and activation contributes to the development of osteoporosis ([@B2]). Thus, to understand the mechanisms underlying how DOE prevents estrogen deficiency-induced osteoporosis, we investigated the effect of this extract on *in vitro* RANKL-induced osteoclastogenesis.

Observations show that numerous TRAP-positive multinucleated osteoclasts formed when RAW264.7 cells were incubated with RANKL for 5 days (**Figure [5A](#F5){ref-type="fig"}**). At the same time, however, DOE treatment significantly inhibited RANKL-induced osteoclast formation (*P* \< 0.001; **Figures [5A,B](#F5){ref-type="fig"}**). Thus, to eliminate the possibility that DOE suppressed osteoclastogenesis is the result of toxicity of this extract on RAW264.7 cells, we performed a MTT assay. Results show that, as expected, concentrations of up to 80 μg/ml DOE had no toxic effects on RAW264.7 cells when they were treated with the extract for 24 and 48 h, respectively (**Figure [5C](#F5){ref-type="fig"}**). This outcome demonstrates that the inhibitory effects of DOE on osteoclastogenesis are independent of cytoxicity.

![DOE treatment inhibits RANKL-induced osteoclastogenesis. **(A)** RAW264.7 cells were cultured for 5 days with RANKL (50 ng/ml) in the presence of XLGB (10 μg/ml) or the indicated concentrations of DOE and then stained for TRAP. **(B)** TRAP-positive multinucleated cells with more than five nuclei were considered mature osteoclasts, as observed under a light microscope. **(C)** The effects of DOE on the viability of RAW264.7 cells as determined by the MTT assay. Representative images were acquired using a light microscope (magnification ×200). Values are means ± SEM for three independent experiments. ^∆∆∆^*P* \< 0.001 versus the control, and ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, and ^∗∗∗^*P* \< 0.001 versus just RANKL-treated cells.](fphar-08-00966-g005){#F5}

DOE Treatment Reduces the Expression of Osteoclast-Specific Marker Genes and Proteins
-------------------------------------------------------------------------------------

As our results demonstrate that DOE suppresses osteoclastogenesis, we further hypothesized that this extract would inhibit the expression of osteoclast-specific marker genes and proteins in RAW264.7 cells following RANKL stimulation. Subsequent qRT-PCR analysis (**Figure [6](#F6){ref-type="fig"}**) revealed that both XLGB and DOE treatments significantly inhibit the messenger RNA (mRNA) expression of osteoclast marker genes, including the nuclear factor of activated T cells (*NFATc1*), *TRAP, cathepsin K, β3-Integrin, c-Fos*, and *c-Src* (*P* \< 0.01 or *P* \< 0.001). In addition, consistent with these qRT-PCR results, western blot analysis also demonstrates that the protein expression of NFATc1, c-Fos, c-Src, and cathepsin K tends to be down-regulated by XLGB and DOE treatments during osteoclastogenesis (**Figure [7](#F7){ref-type="fig"}**). Collectively, these results strongly indicate that DOE treatment effectively inhibits RANKL-mediated osteoclastogenesis in RAW264.7 cells.

![DOE treatment reduces the expression of osteoclast-specific marker genes. Values are means ± SEM of three independent experiments. ^∆\ ∆\ ∆^*P* \< 0.001 versus the control, and ^∗∗^*P* \< 0.01, and ^∗∗∗^*P* \< 0.001 versus just RANKL-treated cells.](fphar-08-00966-g006){#F6}

![DOE treatment reduces the expression of osteoclast-specific marker proteins. In this experiment, c-Fos, NFATc1, c-Src, cathepsin K, and β-tubulin levels were all detected using western blotting, and results were quantified using the software AlphaView. Representative images are displayed; values are the means ± SEM of three independent experiments.](fphar-08-00966-g007){#F7}

Discussion
==========

The orchid *D. officinale* possesses unique medicinal properties, and has been widely utilized in Asian traditional medicine for the prevention and treatment of various ailments, including obesity, diabetes, hypertension, hyperlipidemia, inflammation, and cancer ([@B24]; [@B22]; [@B44]). A close relative, *D. moniliforme*, another medicinal orchid, has also recently been reported to exert inhibitory effects on both *in vitro* RANKL-induced osteoclast differentiation and *in vivo* lipopolysaccharide-induced bone erosion ([@B1]). Previous studies have shown, however, that the chemical composition and quantity of compounds are markedly different between these two orchids; indeed, the subject of this study, *D. officinale*, is likely of higher quality and medicinal value compared to *D. moniliforme* given the same chemical compositions ([@B4]). We therefore hypothesize that *D. officinale* can play an important role in treating osteoporosis and inhibiting osteoclast differentiation. Consistent with this hypothesis, we have shown that DOE treatment significantly mitigates osteoporosis *in vivo* and inhibits *in vitro* osteoclast differentiation. In order to carry out the experiment better, we preformed the quality assessment by chemical composition analysis. Interestingly, based on the previously study, narigenin had the effect of anti-bone resorption ([@B30]), and it was possible that narigenin played a role in anti-PMOP. The aim of our future work will be to further investigate the bioactive compounds responsible for this anti-osteoporotic effect.

As discussed, estrogen is a crucial regulator of bone quality. The role of this hormone in human bone health is well-illustrated by the fact that an estrogen deficiency can promote the development of PMOP ([@B32]; [@B31]; [@B3]; [@B38]; [@B47]). It is also well-established that an ovariectomy can result in osteoporosis correlated with a significant increase in body weight and bone resorption, a dramatic decrease in uterine weight and BMD as well as deterioration of bone microarchitecture; all these changes are largely the result of estrogen deficiencies ([@B49]). Although hormone supplements can ameliorate these issues, as discussed above, adverse effects on other tissues are inevitable ([@B3]). Thus, the use of natural products as treatments for osteoporosis should be explored as these will have less side effects. We investigated the osteoprotective effects of DOE on PMOP in this study using an OVX rats model. Results show that DOE exhibits potent anti-osteoporotic capabilities but cannot reverse OVX-induced body weight gains. It is also noteworthy that while DOE treatment ameliorated both lipid and glucose metabolism in OVX rats at the biochemical level, these changes were not significant. Nevertheless, our results indicate that DOE treatment may inhibit osteoporosis without lowering unwanted body weight gains, while improving the metabolism of lipids and glucose.

Levels of estrogen are dramatically reduced following ovariectomies and this can seriously impair both bone mass and architecture ([@B17]; [@B18]). The results of this study show that both medium- and high-dose DOE treatments significantly elevated the E~2~ level in OVX rats, indicating that this extract may exert phytoestrogenic effects mainly via estrogen receptor α signaling ([@B13]; [@B38]). In addition, losses of calcium and phosphorus are also obvious pathological features in patients with osteoporosis, and so treatments for osteoporosis that are based on these elements (e.g., bisphosphonates) are widely applied ([@B6]). Interestingly, the results of this study show that OVX-induced calcium and phosphorus losses were both significantly alleviated by DOE treatment, which suggests that this extract might be able to effectively maintain homeostasis of these elements. We used a series of formation and resorption parameters to evaluate the mechanisms of DOE treatment on bone metabolic biomarkers; the activities of both ALP and BGP have been widely applied in this context as markers of bone formation ([@B49]). The results of this study show that DOE treatment significantly reduced the activities of both markers in OVX rats, indicating a decreasing rate of bone turnover. In addition, levels of ACP, another vital indicator of bone resorption ([@B28]), were significantly enhanced in OVX rats; interestingly, DOE treatment markedly suppressed the activity of ACP in OVX rats. Our results indicate that DOE treatment prevents OVX-induced osteoporosis mainly by exerting a two-way regulatory effect on bone metabolism.

Uterine atrophy is another commonly observed phenomenon in OVX rats, following a remarkable reduction in the weight of this organ ([@B28]). Notably, the results of this study show that DOE treatment significantly increased uterine weight, the organ coefficient of the uterus, and endometrial height in OVX rats, indicating that this extract can effectively reverse uterine atrophy. However, the same effect on femoral physical parameters was not seen; wet and dry weight, organ coefficients, diameter, and length all remained unaffected in OVX rats following DOE treatment. It is well-known that femoral BMD, biomechanical properties, and microarchitecture can be used as proxies for bone quality ([@B28]). The results of this study show that DOE treatment significantly increases femoral BMD in OVX rats but does not significantly change femoral biomechanical properties (i.e., maximum deflection and load). More interestingly, DOE treatment notably increases cortical bone thickness and trabecular area in the femur of OVX rats; this result strongly suggests that DOE can effectively mitigate bone microarchitectural deterioration. These results therefore suggest that DOE treatment will have a very positive protective effect on bone quality.

Bone mass is tightly regulated by a delicate balance between osteoblast formation and osteoclast resorption; the excess differentiation and activation of osteoclasts causes osteoporosis ([@B32]). Thus, in order to investigate whether DOE treatment can inhibit osteoclastogenesis, we carried out TRAP staining using a series of RAW264.7 cells, one well-established preosteoclast cell line for the study of this process ([@B28]). Our results show that DOE treatment can effectively inhibit RANKL-mediated osteoclastogenesis in RAW264.7 cells and suppress the expression of osteoclast-specific marker genes and proteins during this process. Most importantly, our *in vivo* experiments show that DOE treatment exerts two-way regulatory effects on bone metabolism. Further work is needed, however, to address the question of whether, or not, DOE treatment can simultaneously inhibit bone resorption and promote formation. According to previous study on osteoclastogenesis, the signal transduction pathways including the proteins p38, c-jun N-terminal kinase (JNK), and Akt are activated in response to the direct binding of RANK and RANKL ([@B25]; [@B12]; [@B33]). However, it currently remains unclear whether, or not, RANKL-induced phosphorylation of these signaling pathways was associated with the anti-osteoclastogenic effect of DOE. The precise mechanisms and bioactive compounds involved in osteoclastogenesis inhibition via DOE treatment need to be clarified.

Conclusion
==========

In this study, we have shown that DOE treatment can prevent ovariectomy-induced osteoporosis *in vivo* and inhibit RANKL-induced osteoclast differentiation *in vitro*. Our results suggest that DOE may have a promising role to play in the future treatment of osteoporosis caused by estrogen deficiencies.
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